spacer
home > ebr > spring 2019 > details matter
PUBLICATIONS
European Biopharmaceutical Review

Details Matter

The transition from uni- to multicellular organisms was marked by an increase in the complexity of cell surface proteins that allowed intercellular communication and stable cell adhesion (1). The surfaceome (the collection of proteins residing at the cell surface) acts as the interface between a cell and its environment, mediating crucial cellular behaviours such as cell-cell communication, self and non-self recognition, and cell signalling. Additionally, the surfaceome largely dictates the shape, polarity, differentiation, and motility of cells. Given the crucial role of surface-associated proteins in every aspect of cellular life, they are, unsurprisingly, the molecular targets for roughly 70% of FDA approved drugs (2).

The aforementioned functions of the surfaceome are mediated through interactions of proteins in the cell membrane of the same cell (cis) and through interactions with proteins of neighbouring cells, the extracellular matrix, and circulating ligands (trans). The collection of cis and trans interactions is overall referred to as extracellular proteinprotein interactions (ePPIs). For a cell to adapt quickly in a changing microenvironment and respond fast to stimuli while retaining the necessary plasticity, ePPIs are usually transient with low affinities (μM to mM range) to allow for fast dissociation rates. Additionally, surface proteins have a few distinct properties compared to their intracellular counterparts. Firstly, correct folding of these proteins is largely dependent on an oxidising environment for the formation of disulphide bonds. Secondly, given that more than 90% of vertebrate surface proteins are glycosylated, correct folding also requires specialised chaperons and glycosylation machinery (3). Thirdly, membrane-spanning proteins are largely amphipathic due to hydrophilic glycans decorating the extracellular part and stretches of hydrophobic amino acids that span the membrane.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Maria P Pavlou received her PhD in translational proteomics from the Department of Laboratory Medicine and Pathobiology at University of Toronto, Canada. Upon PhD completion, Maria moved to Switzerland to pursue a postdoctoral fellowship in the Institute of Molecular Systems Biology at the Swiss Federal Institute of Technology (ETH) in Zürich, focussing on host-pathogen interactions. In 2017, she joined Dualsystems Biotech as a senior scientist, and, a year later, she was promoted to Chief Scientific Officer, leading the research team to develop further the LRC methodology and establish new services.

Dr Paul Helbling did his Master’s degree in biology at the University of Zürich, Switzerland, and obtained his PhD in developmental biology at ETH Zürich. After his PhD, he worked at the Foundation for Cardiovascular Research and organised clinical studies according to Good Clinical Practice. Paul then moved on to MDS Pharma Services, where he became responsible for the ligand binding group that specialised inthe analysis of biologics and antidrug antibodies. His next position was in business development at Solvias, responsible for southern Europe and Germany and opening new market territories in Turkey. Paul then became Head of Business Development at IBR, before joining the team at Dualsystems Biotech as CEO, focussing on identifying targets and off-targets on the living cells using liquid chromatographymass spectrometry.
spacer
Dr Maria P Pavlou
spacer
spacer
spacer
Dr Paul Helbling
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Biopharma Group Celebrates Its 30th Anniversary

Established in 1989 as Biopharma Process Systems Ltd., the company initially focused on freeze drying equipment to the pharmaceutical & biotechnology industries and fast became a leading supplier of equipment in the UK & Ireland. In 1997, Biopharma Technology Ltd. was formed to offer a freeze drying R&D consultancy and lab services, with Dr. Kevin Ward joining the team in 2000 to expand the in-house expertise, services and training courses.
More info >>

White Papers

Streamlining patient recruitment using EHR data

The field of (bio)pharmaceutical research is booming. Increasingly more innovative therapeutics are being developed with the ability to drastically improve the quality of life of millions of patients around the world. Rigorously testing each of these candidate drugs for their safety and efficacy is an essential part of the development process. As the number of clinical trials steadily increases, the search for patients who present a specific medical profile and are willing to participate intensifies.
More info >>

 
Industry Events

Respiratory Drug Delivery (RDD®) Europe 2019

7-10 May 2019, Estoril Congress Center, Lisbon

Respiratory Drug Delivery (RDD®) Europe 2019 connects emerging and high-level scientists, academics, industrial and regulatory specialists, and clinicians. It is a must-attend conference for companies involved in research, development, testing or marketing of medicines, devices and services associated with pulmonary or nasal pharmaceutical products. This year, RDD Europe 2019 will be held in Estoril (Lisbon), Portugal, May 7-10, 2019, and, as in previous years is jointly organized by RDD Online and Aptar Pharma.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement